Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
This article examines the use of animal models in studying progressive forms of multiple sclerosis, discussing both the insights gained and the methodological challenges encountered. It addresses how preclinical animal research contributes to understanding MS pathophysiology while acknowledging limitations in translating findings to human disease.
This large pooled analysis of 4,241 RRMS patients from phase 3 trials examined how chronological age influences brain volume changes over 96 weeks of follow-up. Older participants showed lower baseline brain volumes but exhibited significantly slower atrophy rates during follow-up compared to younger patients, particularly in the thalamus.
The article reviews evidence-based management of MS relapses using high-dose corticosteroids while distinguishing true MS-related symptoms from transient worsening caused by systemic factors. It emphasizes shared decision-making for selecting higher-efficacy therapies or escalation strategies, with appropriate screening and ongoing safety monitoring, noting that benefits vary between relapsing and progressive MS presentations.
This epidemiological study estimated the annual MS incidence in Switzerland at 7.7 per 100,000 inhabitants (approximately 663 cases annually) from 2017-2021, with stable rates across the study period and higher incidence in women than men. Peak incidence occurred in the 30-35 age group for women and 35-40 for men, with most newly diagnosed individuals receiving disease-modifying therapies.
This cross-sectional study of 205 MS patients found episodic migraine in 17.56% of participants, with higher prevalence in those under 40 years old. The majority of migraines presented without aura, and no cases of chronic migraine were detected in the cohort.
